Carlyle and SK Capital Partners have announced an extension of their tender offer to acquire all outstanding common stock of bluebird bio, Inc. The new expiration date for this offer, initially set for May 2, 2025, is now one minute after 11:59 p.m. on May 12, 2025. This extension was made to allow more time for fulfillment of the remaining conditions, including obtaining regulatory approvals.
Equiniti Trust Company, the offer’s depositary, reported that as of May 1, 2025, approximately 936,791 shares of bluebird’s common stock were tendered and not withdrawn. Shareholders who have already tendered their shares do not need to take further action due to this extension.
The offer is being made under the terms set in the Offer to Purchase document from March 7, 2025. It requires certain conditions, such as the tender of a majority of bluebird’s shares and relevant regulatory approvals, to be met.
“Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade,” the company’s statement elucidates. They emphasize their focus on severe genetic diseases, spotlighting programs for conditions such as sickle cell disease and ß-thalassemia.
Carlyle, listed on NASDAQ under the ticker CG, operates a global investment firm managing $441 billion in assets as of late 2024. SK Capital, a private investment firm, focuses on sectors like life sciences and specialty materials, managing around $9 billion in assets and generating $12 billion annually.
This communication, filed as a Tender Offer Statement on Schedule TO, is not a solicitation of offers to sell any securities of bluebird. Relevant documents are available for free on the SEC’s website and bluebird’s investor section. Investors are advised to read these meticulously before making decisions concerning the offer.
For more details, stakeholders can contact designated representatives from bluebird, Carlyle, and SK Capital.
